Orally delivered malaria vaccines: not too hard to swallow

Bibliography

• HILLEMAN MR: Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine (2000) 18(15):1436–1447.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Achievements in public health, 1990-1999: impact of vaccines universally recommended for children. Morb. Mortal. Wkly Rep. (1999) 48:243–248.
   PubMedGoogle Scholar
• TRIGG PI, KONDRACHINE AV: The current global malaria situation. In: Malaria: Parasite Biology, Pathogenesis and Protection. Sherman IW (Ed.), ASM Press,Washington DC, USA (1998):11–22.
   Google Scholar
• MOORTHY VS, GOOD ME HILL AV: Malaria vaccine developments. Lancet (2004) 363(9403):150–156.
   PubMed Web of Science ®Google Scholar
• ••A recent review on malaria vaccinedevelopment, with highlights on thecandidate vaccine antigens that have reached clinical trials.
   Google Scholar
• GILLES HM: The malaria parasites. In: Bruce-Chwatt's Essential Malariology Gilles HM, Warrell DA (Ms), Edward Arnold, London, UK (1993):12–34.
   Google Scholar
• WEBSTER D, HILL AV: Progress with new malaria vaccines. Bull. World Health Organ. (2003) 81(12):902–909.
   PubMed Web of Science ®Google Scholar
• WEBSTER DE, GAHAN ME, STRUGNELL RA, WESSELINGH SW: Advances in oral vaccine delivery options: what is on the horizon? Am. I Drug Deify. (2003) 1(4):227–240.
   Google Scholar
• OGRA PL, FADEN H, WELLIVER RC: Vaccination strategies for mucosal immune responses. Clin. Microbiol Rev (2001) 14(2):430–445.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review onvaccination strategies for induction of mucosal immunity.
   Google Scholar
• WANG L, KEDZIERSKI L,WESSELINGH SL, COPPEL RL: Oral immunization with a recombinant malariaprotein induces conformational antibodies and protects mice against lethal malaria. Infect. Immun. (2003) 71(5):2356–2364.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration that oraladministration of recombinant Plasmodium proteins can provide protection against malaria.
   Google Scholar
• KEDZIERSKI L, BLACK CG,COPPEL RL: Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge. Infect. Immun. (2000) 68(10):6034–6037.
   PubMed Web of Science ®Google Scholar
• WANG L, GOSCHNICK M,COPPEL RL: Oral immunisation with a combination of Plasmodium yoebimerozoite surface protein 1 and 4/5 enhances protection against lethal malaria challenge. Infect. Immun. (2004) (In Press).
   Google Scholar
• LEWIS AP: Cloning and analysis of the gene encoding the 230-kilodalton merozoite surface antigen of Plasmodium yoebi MM. Biochem. Parasitol (1989) 36(3):271–282.
   PubMed Web of Science ®Google Scholar
• KEDZIERSKI L, BLACK C, COPPEL RL: Characterisation of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodium yoelii. Mol Biochem. Parasitol (2000) 105(1):137–147.
   PubMed Web of Science ®Google Scholar
• MARSHALL VM, SILVA A, FOLEY M et al.: A second merozoite surface protein (MSP-4) of Plasmodium fakiparum that contains an epidermal growth factor-like domain. Infect. Immun. (1997) 65(11):4460–4467.
   PubMed Web of Science ®Google Scholar
• MEDINA E, GUZMAN CA: Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine (2001) 19(13-14):1573–1580.
   PubMed Web of Science ®Google Scholar
• •This review summarises the vaccine delivery systems based on live bacterial vectors, and discusses their potential and limitations.
   Google Scholar
• GARMORY HS, BROWN KA,TITBALL RW: Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev (2002) 26(4)339–353.
   Google Scholar
• TACKET CO, SZTEIN MB, LOSONSKY GA et al.: Safety of live oral Salmonella Ophivaccine strains with deletions in htrA and aroC aroD and immune response in humans. aInfect. Inman. (1997) 65(2):452–456.
   PubMed Web of Science ®Google Scholar
• TACKET CO, SZTEIN MB, WASSERMAN SS et al: Phase II clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in US volunteers. Infect. Inman. (2000) 68(3):1196–1201.
   PubMed Web of Science ®Google Scholar
• TACKET CO, GALEN J, SZTEIN MB et al.: Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin. Immunol (2000) 97(2):146–153.
   PubMed Web of Science ®Google Scholar
• MASTROENI P, CHABALGOITY JA, DUNSTAN SJ, MASKELL DJ, DOUGAN G: Salmonella: immune responses and vaccines. Vet. (2001) 161(2):132–164.
   PubMed Web of Science ®Google Scholar
• BUMANN D, HUECK C,AEBISCHER T, MEYER TF: Recombinant live Salmonella spp. for human vaccination against heterologous pathogens. FEMS Iinmunol. Med. Microbiol (2000) 27(4):357–364.
   PubMed Web of Science ®Google Scholar
• HOFFMAN SL, FRANKE ED, HOLLINGDALE MR, DRUILHE P: Attacking the infected hepatocyte. In: Malaria Vaccine Development: A Multi-Immune Response Approach.Hoffman SL (Ed.), ASM Press, Washington DC, USA (1996):35–76.
   Google Scholar
• SAD OFF JC, BALLOU WR, BARON LSet al: Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science (1988) 240(4850):336–338.
   PubMed Web of Science ®Google Scholar
• •The first demonstration that oral immunisation with attenuated recombinant Salmonella can induce protective immunity against malaria infection.
   Google Scholar
• AGGARWAL A, KUMAR S, JAFFE R et al.: Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. Exp. Med. (1990) 172(4):1083–1090.
   PubMed Web of Science ®Google Scholar
• FLYNN JL, WEISS WR, NORRIS KA et al: Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Ma Microbiol (1990) 4(12):2111–2118.
   PubMed Web of Science ®Google Scholar
• RUIZ-PEREZ F, LEON-KEMPIS R, SANTIAGO-MACHUCA A et al.: Expression of the Plasmodium fakiparum immunodominant epitope (NANP) (4) on the surface of Salmonella enterica using the autotransporter MisL. Infect. Immun. (2002) 70(7):3611–3620.
   PubMed Web of Science ®Google Scholar
• GONZALEZ C, HONE D,NORIEGA FR et al: Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium fakiparum: strain construction and safety and immunogenicity in humans. I Infect. Dis. (1994) 169(4):927–931.
   PubMed Web of Science ®Google Scholar
• HOLDER AA: Preventing merozoite invasion of erythrocytes. In: Malaria Vaccine Development: A Multi-Immune Response Approach. Hoffman SL (Ed.), ASM Press, Washington DC, USA (1996):77–104.
   Google Scholar
• TOEBE CS, CLEMENTS JD, CARDENAS L, JENNINGS GJ,WISER MF: Evaluation of immunogenicity of an oral Salmonella vaccine expressing recombinant Plasmodium berghei merozoite surface protein-1. Am. I Trop. Med. Hyg. (1997) 56(2):192–199.
   PubMed Web of Science ®Google Scholar
• CRISANTI A, MULLER HM,HILBICH C et al.: Epitopes recognized by human T cells map within the conserved part of the GP190 of I? fakiparum. Science (1988) 240(4857):1324–1326.
   Google Scholar
• GOMEZ-DUARTE OG, PASETTI ME SANTIAGO A et al: Expression, extracellular secretion, and immunogenicity of the Plasmodium fakiparum sporozoite surface protein 2 in Salmonella vaccinestrains. Infect. Immun. (2001)69(2):1192–1198.
   PubMed Web of Science ®Google Scholar
• SCHORR J, KNAPP B, HUNDT E, KUPPER HA, AMANN E: Surface expression of malarial antigens in Salmonella typhimurium: induction of serum antibody response upon oral vaccination of mice. Vaccine (1991) 9(9):675–681.
   PubMed Web of Science ®Google Scholar
• HADDAD D, LILJEQVIST S, KUMAR S et al.: Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. FEMS Immunol Med. Microbiol (1995) 12(3-4):175–186.
   PubMed Web of Science ®Google Scholar
• SOMNER EA, OGUN SA, SINHA KA et al.: Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains. Microbiology(1999) 145(Pt 1):221–229.
   PubMedGoogle Scholar
• WU S, BEIER M, SZTEIN MB et al: Construction and immunogenicity in mice of attenuated Salmonella typhi expressing Plasmodium fakiparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C. Biotechnol (2000) 83(1-2):125–135.
   Google Scholar
• GOMEZ-DUARTE OG, GALEN J, CHATFIELD SN et al.: Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain. Vaccine (1995) 13(16):1596–1602.
   PubMed Web of Science ®Google Scholar
• CARDENAS L, CLEMENTS JD: Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors. Vaccine (1993) 11(2):126–135.
   PubMed Web of Science ®Google Scholar
• STRUGNELL RA, MASKELL D, FAIRWEATHER N et al: Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains. Gene (1990) 88(1):57–63.
   PubMed Web of Science ®Google Scholar
• DUNSTAN SJ, SIMMONS CP,STRUGNELL RA: Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. Typhimurium. Infect. Immun. (1999) 67(10):5133–5141.
   PubMed Web of Science ®Google Scholar
• QIAN F, PAN W: Construction of a tetR-integrated Salmonella enterica serovar Typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of Plasmodium fakiparum for applications in human vaccine production. Infect. Immun. (2002) 70(4):2029–2038.
   PubMed Web of Science ®Google Scholar
• ATTRIDGE SR, DAVIES R,LABROOY JT: Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain. Vaccine (1997) 15(2):155–162.
   PubMed Web of Science ®Google Scholar
• SIZEMORE DR, BRANSTROM AA, SAD OFF JC: Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science (1995) 270(5234):299–302.
   PubMed Web of Science ®Google Scholar
• WEISS S, CHAKRABORTY T: Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers. CLIFF. Opin. Biotechnol (2001) 12(5):467–472.
   PubMed Web of Science ®Google Scholar
• DIETRICH G, GENTSCHEV I, HESS J et al: Delivery of DNA vaccines by attenuated intracellular bacteria. Immunol Today (1999) 20(6):251–253.
   PubMedGoogle Scholar
• KUMAR S, EPSTEIN JE, RICHIE TL et al: A multilateral effort to develop DNA vaccines against fakiparum malaria. Trends Parasitol (2002) 18(3):129–135.
   PubMed Web of Science ®Google Scholar
• O'HAGAN DT: Mietopattieles and polymers for the mucosal delivery of vaccines. Adv. Drug Deify. Rev (1998) 34(2–3):305-320.
   Google Scholar
• ZHO F, NEUTRA MR: Antigen delivery to mucosa-associated lymphoid tissues using liposomes as a carrier. Biosci. Rep. (2002) 22(2):355–369.
   PubMed Web of Science ®Google Scholar
• MOWAT AM, SMITH RE,DONACHIE AM et al: Oral vaccination with immune stimulating complexes. Immunol Lett. (1999) 65(1-2):133–140.
   PubMed Web of Science ®Google Scholar
• KANEDA Y: Virosomes: evolution of the liposome as a targeted drug delivery system. Adv. Drug Deify. Rev (2000) 43(2-3):197–205.
   PubMed Web of Science ®Google Scholar
• PUMPENS P, GRENS E: HBV core particles as a carrier for B cell/T cell epitopes. Intervirology (2001) 44(2-3):98–114.
   PubMed Web of Science ®Google Scholar
• TURPEN TH, REINL SJ,CHAROENVIT Y et al.: Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnology (1995) 13(1):53–57.
   Google Scholar
• YASAWARDENE SG,LOMONOSS OFF GP, RAMASAMY R: Expression & immunogenicity of malaria merozoite peptides displayed on the small coat protein of chimaeric cowpea mosaic virus. Indian J. Med. Res. (2003) 118:115–124.
   PubMed Web of Science ®Google Scholar
• KATZ DE, DELORIMIER AJ, WOLF MK et al.: Oral immunization ofadult volunteers with microencapsulated enterotcodgenic Escherichia coil (ETEC) C56 antigen. Vaccine (2003) 21(5-6):341–346.
   PubMed Web of Science ®Google Scholar
• TACKET CO, REID RH, BOEDEKER EC et al.: Enteral immunization and challenge of volunteers given enterotoxigenic E coil CFA/II encapsulated in biodegradable microspheres. Vaccine (1994) 12(14):1270–1274.
   PubMed Web of Science ®Google Scholar
• BALL JM, GRAHAM DY, OPEKUN AR et al.: Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology (1999) 117(1):40–48.
   PubMed Web of Science ®Google Scholar
• KAPUSTA J, MODELSKA A,FIGLEROWICZ M et al: A plant-derivededible vaccine against hepatitis B virus. FASEB J. (1999) 13(13):1796–1799.
   PubMed Web of Science ®Google Scholar
• TACKET CO, SZTEIN MB, LOSONSKY GA, WASSERMAN SS, ESTES MK: Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers.Clin. Immunol (2003) 108(3):241–247.
   Google Scholar
• CHAICUMPA W,CHONGSA-NGUAN M,KALAMBAHETI T et al: Immunogenicity of liposome-associated and refined antigen oral cholera vaccines in Thai volunteers. Vaccine (1998) 16(7):678–684.
   PubMed Web of Science ®Google Scholar
• CHILDERS NK, MICHALEK SM, PRITCHARD DG, MCGHEE JR: Mucosal and systemic responses to an oral liposome-Streptococcus mutans carbohydrate vaccine in humans. Reg. Immunol (1990) 3(6):289–296.
   PubMedGoogle Scholar
• JONES DH, CORRIS S, MCDONALD S, CLEGG JC, FARRAR GH: Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine (1997) 15(8):814–817.
   PubMed Web of Science ®Google Scholar
• KANEKO H, BEDNAREK I, WIERZBICKI A et al.: Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology (2000) 267(1):8–16.
   PubMed Web of Science ®Google Scholar
• SHI W, LIU J, HUANG Y, QIAO L: Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. Vim]. (2001) 75(21):10139–10148.
   Google Scholar
• CARCABOSO AM, HERNANDEZ RIVI, IGARTUA M et al: Immune response afteroral administration of the encapsulatedmalaria synthetic peptide SP(66. Lit. J. Pharm. (2003) 260(2):273–282.This paper describes the oral administration of the synthetic peptide SPF66 encapsulated in PLGA to mice. Immune responses were comparable to those obtained with systemic immunisation in several clinical trials.
   Google Scholar
• AWRAM P, GARDNER RC, FORSTER RL, BELLAMY AR: The potential of plant viral vectors and transgenic plants for subunit vaccine production. Adv. Virus Res. (2002) 58:81–124.
   PubMed Web of Science ®Google Scholar
• DANIELL H, STREATFIELD SJ, WYCOFF K: Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci. (2001) 6(5):219–226.
   PubMed Web of Science ®Google Scholar
• MA JK, DRAKE PM, CHRISTOU P: The production of recombinant pharmaceutical proteins in plants. Nat. Rev Genet. (2003) 4(10):794–805.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review on the application of transgenic plants for the production of vaccine antigens as well as other bioparmaceuticals.
   Google Scholar
• LAMPHEAR BJ, STREATFIELD SJ, JILKA JM et al.: Delivery of subunit vaccines in maize seed. J. Control. Release (2002) 85(1-3):169–180.
   PubMed Web of Science ®Google Scholar
• DE COSA B, MOAR W, LEE SB, MILLER M, DANIELL H: Overexpression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat. Biotechnol (2001) 19(1):71–74.
   PubMed Web of Science ®Google Scholar
• YU J, LANGRIDGE WH: A plant-based multicomponent vaccine protects mice from enteric diseases. Nat. Biotechnol (2001) 19(6):548–552.
   PubMed Web of Science ®Google Scholar
• YE X, AL-BABILI S, KLOTI A et al.: Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm. Science (2000) 287(5451):303–305.
   PubMed Web of Science ®Google Scholar
• TACKET CO, MASON HS, LOSONSKY G et al.: Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. (2000) 182(1):302–305.
   PubMed Web of Science ®Google Scholar
• TACKET CO, MASON HS,LOSONSKY G et al.: Immunogenicity in humans of a recombinant bacterial antigen delivered in a trangenic potato. Nat. Med. (1998) 4(5):607–609.
   Google Scholar
• YUSIBOV V, HOOPER DC, SPITSIN SV et al.: Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine (2002) 20(25-26):3155–3164.
   PubMed Web of Science ®Google Scholar
• GHOSH S, MALHOTRA P,LALITHA PV, GUHA-MUKHERJEE S, CHAUHAN VS: Expression of Plasmodium falcipamm C-terminal region of merozoite surface protein (PfMSP119), a potential malaria vaccine candidate, in tobacco. Plant Science (2002) 162:335–343.
   Web of Science ®Google Scholar
• WANG L, CAMPBELL A, WEBSTER D et al.: Feasibility of using transgenic plants to induce protective immunity against malaria. Exp. Parasitol (2003) 105(1):52.
   Google Scholar
• KAPUSTA J, MODELSKA A,PNIEWSKI T et al.: Oral immunization of human with transgenic lettuce expressing hepatitis B surface antigen. Adv. Exp. Med. Biol. (2001) 495:299–303.
   Google Scholar
• •This paper shows that humans may be immunised orally against hepatitis B virus with lettuce plants expressing the viral antigen. This study provides an example for the use of plant-based vaccines against non-enteric pathogens.
   Google Scholar
• KONG Q, RICHTER L, YANG YF et al: Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA (2001) 98(20):11539–11544.
   PubMed Web of Science ®Google Scholar
• RICHTER LJ, THANAVALA Y, ARNTZEN CJ, MASON HS:Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat. Biotechnol (2000) 18(11):1167–1171.
   PubMed Web of Science ®Google Scholar
• HAQ TA, MASON HS, CLEMENTS JD, ARNTZEN CJ: Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science (1995) 268(5211):714–716.
   PubMed Web of Science ®Google Scholar
• GARDNER MI, HALL N, FUNG E et al: Genome sequence of the human malaria parasite Plasmodium fakiparum. Nature (2002) 419(6906):498–511.
   PubMed Web of Science ®Google Scholar
• PAN W, RAVOT E, TOLLE R et al: Vaccine candidate MSP-1 from Plasmodium falcipamm: a redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from Escherichia cob and mammalian cells. Nucleic Acids Res. (1999) 27(4):1094–1103.
   PubMed Web of Science ®Google Scholar
• DANIELL H, LEE SB, PANCHAL T, WIEBE PO: Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenictobacco chloroplasts. Ma Biol. (2001) 311(5):1001–1009.
   Web of Science ®Google Scholar
• DANIELL H, KHAN MS, ALLISON L: Milestones in chloroplast genetic engineering: an environmentally friendly era in biotechnology. Trends Plant Sci. (2002) 7(2):84–91.
   PubMed Web of Science ®Google Scholar
• •This review summarises the application of chloroplast transformation on vaccine production in plants, with highlights on its potential for multigene engineering and high-level transgene expression.
   Google Scholar
• HATHAWAY LJ, KRAEHENBUHL JP: The role of M cells in mucosal immunity. Cell. Ma Life Sri. (2000) 57(2):323–332.
   PubMed Web of Science ®Google Scholar
• ALTARE F, LAMMAS D, REVY P et al: Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. Clin. Invest. (1998) 102(12):2035–2040.
   Google Scholar
• DE JONG R, ALTARE F, HAAGEN IA et al: Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science (1998) 280(5368):1435–1438.
   PubMed Web of Science ®Google Scholar
• RIGANO MM, ALVAREZ ML, PINKHASOV J et al.: Production of a fusion protein consisting of the enterotwdgenic Escherichia cob heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana. Plant Cell Rep. (2004) 22(7):502–508.
   PubMed Web of Science ®Google Scholar
• CHEN H, TORCHILIN V, LANGER R: Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res. (1996) 13(9):1378–1383.
   PubMed Web of Science ®Google Scholar
• RESCIGNO M: Identification of a new mechanism for bacterial uptake at mucosal surfaces, which is mediated by dendritic cells. Pathol Biol. (Paris) (2003) 51(2):69–70.
   PubMed Web of Science ®Google Scholar
• WIERZBICKI A, KISZKA I, KANEKO H et al: Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein. Vaccine (2002) 20(9-10):1295–1307.
   PubMed Web of Science ®Google Scholar
• STROBEL S, MOWAT AM: Immune responses to dietary antigens: oral tolerance. Immunol Today (1998) 19(4):173–181.
   PubMedGoogle Scholar
• BLANAS E, CARBONE FR, ALLISON J, MILLER IF, HEATH WR: Induction of autoimmune diabetes by oral administration of autoantigen. Science (1996) 274(5293):1707–1709.
   PubMed Web of Science ®Google Scholar
• WIENDL H, HOHLFELD R: Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs (2002) 16(3):183–200.
   PubMed Web of Science ®Google Scholar
• ELSON CO, EALDING W: Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. Immunol (1984) 133(6):2892–2897.
   Web of Science ®Google Scholar
• PLANT A, WILLIAMS R, JACKSON ME, WILLIAMS NA: The B subunit of Escherichia cob heat labile enterotoxin abrogates oral tolerance, promoting predominantly Th2-type immune responses. Eur. Immunol (2003) 33(11):3186–3195.
   PubMed Web of Science ®Google Scholar
• KAPIKIAN AZ: A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal. Novartis Found. Symp. (2001) 238:153-171; discussion 171–159.
   Google Scholar
• PETER G, MYERS MG: Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics (2002) 110(6):e67.
   PubMed Web of Science ®Google Scholar
• QADRI F, AHMED T, AHMED F et al: Safety and immunogenicity of an oral, inactivated enterotwdgenic Escherichia cob plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age. Vaccine (2003) 21(19-20):2394–2403.
   PubMed Web of Science ®Google Scholar
• KOTLOFF KL, TAYLOR DN,SZTEIN MB et al.: Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect. Immun. (2002) 70(4):2016–2021.
   Google Scholar
• JIRATHITIKAL V, SOOKSATHAN P, METADILOGKUL 0,BOURINBAIAR AS: V-1 Immunitor: oral therapeutic AIDS vaccine with prophylactic potential. Vaccine (2003) 21(7-8):624–628.
   PubMedGoogle Scholar
• GOOD MF, DOOLAN DL: Immune effector mechanisms in malaria. Can: Opin. Immunol (1999) 11(4):412–419.
   PubMed Web of Science ®Google Scholar
• ••A review outlining theimmune mechanisms against the pre-erythrocytic, asexual erythrocytic and sexual stages of Plasmodium.
   Google Scholar
• AGNIESZKA AE, WANG L, BLACK CG, COPPEL RU: Merozoite cell biology. In: Malaria Parasites: Cenomes and Molecular Biology Waters AP, Janse CJ (Eds), Caister Academic Press, Wymondham, UK (2004):365–444.
   Google Scholar
• KASLOW DC, QUAKYI IA, SYIN C et al: A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature (1988) 333(6168):74–76.
   PubMed Web of Science ®Google Scholar
• DUFFY PE, KASLOW DC: A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as fakiparum malaria transmission-blocking vaccines. Infect. Inman. (1997) 65(3):1109–1113.
   PubMed Web of Science ®Google Scholar